139 related articles for article (PubMed ID: 37379494)
1. Mortality Benefit of a Blood-Based Biomarker Panel for Lung Cancer on the Basis of the Prostate, Lung, Colorectal, and Ovarian Cohort.
Irajizad E; Fahrmann JF; Marsh T; Vykoukal J; Dennison JB; Long JP; Do KA; Feng Z; Hanash S; Ostrin EJ
J Clin Oncol; 2023 Sep; 41(27):4360-4368. PubMed ID: 37379494
[TBL] [Abstract][Full Text] [Related]
2. Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment.
Fahrmann JF; Marsh T; Irajizad E; Patel N; Murage E; Vykoukal J; Dennison JB; Do KA; Ostrin E; Spitz MR; Lam S; Shete S; Meza R; Tammemägi MC; Feng Z; Hanash SM
J Clin Oncol; 2022 Mar; 40(8):876-883. PubMed ID: 34995129
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self-reporting as Indigenous and non-Indigenous.
Tammemägi MC; Cina K; Kitts AKB; Koop D; Petereit MA; Sargent M; Petereit DG
Cancer; 2023 Dec; 129(24):3894-3904. PubMed ID: 37807694
[TBL] [Abstract][Full Text] [Related]
4. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study.
Tammemägi MC; Ruparel M; Tremblay A; Myers R; Mayo J; Yee J; Atkar-Khattra S; Yuan R; Cressman S; English J; Bedard E; MacEachern P; Burrowes P; Quaife SL; Marshall H; Yang I; Bowman R; Passmore L; McWilliams A; Brims F; Lim KP; Mo L; Melsom S; Saffar B; Teh M; Sheehan R; Kuok Y; Manser R; Irving L; Steinfort D; McCusker M; Pascoe D; Fogarty P; Stone E; Lam DCL; Ng MY; Vardhanabhuti V; Berg CD; Hung RJ; Janes SM; Fong K; Lam S
Lancet Oncol; 2022 Jan; 23(1):138-148. PubMed ID: 34902336
[TBL] [Abstract][Full Text] [Related]
5. OWL: an optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations.
Pan Z; Zhang R; Shen S; Lin Y; Zhang L; Wang X; Ye Q; Wang X; Chen J; Zhao Y; Christiani DC; Li Y; Chen F; Wei Y
EBioMedicine; 2023 Feb; 88():104443. PubMed ID: 36701900
[TBL] [Abstract][Full Text] [Related]
6. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
[TBL] [Abstract][Full Text] [Related]
7. Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model.
Lu MT; Raghu VK; Mayrhofer T; Aerts HJWL; Hoffmann U
Ann Intern Med; 2020 Nov; 173(9):704-713. PubMed ID: 32866413
[TBL] [Abstract][Full Text] [Related]
8. Addressing Sex Disparities in Lung Cancer Screening Eligibility: USPSTF vs PLCOm2012 Criteria.
Pasquinelli MM; Tammemägi MC; Kovitz KL; Durham ML; Deliu Z; Guzman A; Rygalski K; Liu L; Koshy M; Finn P; Feldman LE
Chest; 2022 Jan; 161(1):248-256. PubMed ID: 34252436
[TBL] [Abstract][Full Text] [Related]
9. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO
Weber M; Yap S; Goldsbury D; Manners D; Tammemagi M; Marshall H; Brims F; McWilliams A; Fong K; Kang YJ; Caruana M; Banks E; Canfell K
Int J Cancer; 2017 Jul; 141(2):242-253. PubMed ID: 28249359
[TBL] [Abstract][Full Text] [Related]
10. A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies.
Ten Haaf K; Bastani M; Cao P; Jeon J; Toumazis I; Han SS; Plevritis SK; Blom EF; Kong CY; Tammemägi MC; Feuer EJ; Meza R; de Koning HJ
J Natl Cancer Inst; 2020 May; 112(5):466-479. PubMed ID: 31566216
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the accuracy of the PLCO
Jantzen R; Ezer N; Camilleri-Broët S; Tammemägi MC; Broët P
CMAJ Open; 2023; 11(2):E314-E322. PubMed ID: 37041013
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.
Tammemägi MC; Church TR; Hocking WG; Silvestri GA; Kvale PA; Riley TL; Commins J; Berg CD
PLoS Med; 2014 Dec; 11(12):e1001764. PubMed ID: 25460915
[TBL] [Abstract][Full Text] [Related]
13. Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation.
Tammemagi CM; Pinsky PF; Caporaso NE; Kvale PA; Hocking WG; Church TR; Riley TL; Commins J; Oken MM; Berg CD; Prorok PC
J Natl Cancer Inst; 2011 Jul; 103(13):1058-68. PubMed ID: 21606442
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patients.
Walter J; Kauffmann-Guerrero D; Muley T; Reck M; Fuge J; Günther A; Majeed RW; Savai R; Koch I; Dinkel J; Schneider C; Senghas K; Kobinger S; Manapov F; Thomas M; Kahnert K; Winter H; Behr J; Tammemägi M; Tufman A
Cancer Med; 2023 Apr; 12(7):8880-8896. PubMed ID: 36707972
[TBL] [Abstract][Full Text] [Related]
15. Risk Prediction Model Versus United States Preventive Services Task Force Lung Cancer Screening Eligibility Criteria: Reducing Race Disparities.
Pasquinelli MM; Tammemägi MC; Kovitz KL; Durham ML; Deliu Z; Rygalski K; Liu L; Koshy M; Finn P; Feldman LE
J Thorac Oncol; 2020 Nov; 15(11):1738-1747. PubMed ID: 32822843
[TBL] [Abstract][Full Text] [Related]
16. Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven other risk prediction models.
Liao W; Coupland CAC; Burchardt J; Baldwin DR; ; Gleeson FV; Hippisley-Cox J
Lancet Respir Med; 2023 Aug; 11(8):685-697. PubMed ID: 37030308
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results: A Secondary Analysis of Data From the National Lung Screening Trial.
Tammemägi MC; Ten Haaf K; Toumazis I; Kong CY; Han SS; Jeon J; Commins J; Riley T; Meza R
JAMA Netw Open; 2019 Mar; 2(3):e190204. PubMed ID: 30821827
[TBL] [Abstract][Full Text] [Related]
18. Lung cancer risk discrimination of prediagnostic proteomics measurements compared with existing prediction tools.
Feng X; Wu WY; Onwuka JU; Haider Z; Alcala K; Smith-Byrne K; Zahed H; Guida F; Wang R; Bassett JK; Stevens V; Wang Y; Weinstein S; Freedman ND; Chen C; Tinker L; Nøst TH; Koh WP; Muller D; Colorado-Yohar SM; Tumino R; Hung RJ; Amos CI; Lin X; Zhang X; Arslan AA; Sánchez MJ; Sørgjerd EP; Severi G; Hveem K; Brennan P; Langhammer A; Milne RL; Yuan JM; Melin B; Johansson M; Robbins HA; Johansson M
J Natl Cancer Inst; 2023 Sep; 115(9):1050-1059. PubMed ID: 37260165
[TBL] [Abstract][Full Text] [Related]
19. Race & sex disparities related to low-dose computed tomography lung cancer screening eligibility criteria: A lung cancer cases review.
Williams RM; Kareff SA; Sackstein P; Roy T; Luta G; Kim C; Taylor KL; Tammemägi MC
Lung Cancer; 2022 Jul; 169():55-60. PubMed ID: 35644087
[TBL] [Abstract][Full Text] [Related]
20. Randomization to screening for prostate, lung, colorectal and ovarian cancers and thyroid cancer incidence in two large cancer screening trials.
O'Grady TJ; Kitahara CM; DiRienzo AG; Boscoe FP; Gates MA
PLoS One; 2014; 9(9):e106880. PubMed ID: 25192282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
